Ocular dominance plasticity under metabotropic glutamate receptor blockade

Science

Volumn 272, Issue 5261, 1996, Pages 554-557

  Hensch, Takao K ^a   Stryker, Michael P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; METABOTROPIC RECEPTOR; PHOSPHATIDYLINOSITIDE;

AGE; ANIMAL EXPERIMENT; ARTICLE; BIOCHEMISTRY; CAT; EYE DOMINANCE; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION; VISUAL CORTEX;

EID: 0030005117     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.272.5261.554     Document Type: Article

References (69)

1. T. N. Wiesel and D. H. Hubel, J. Neurophysiol 26, 1003 (1963); C. J Shatz and M. P. Stryker, J. Physiol. 281, 267 (1978); C. J. Shatz, Neuron 5, 745 (1990).
2. T. N. Wiesel and D. H. Hubel, J. Neurophysiol 26, 1003 (1963); C. J Shatz and M. P. Stryker, J. Physiol. 281, 267 (1978); C. J. Shatz, Neuron 5, 745 (1990).
3. T. N. Wiesel and D. H. Hubel, J. Neurophysiol 26, 1003 (1963); C. J Shatz and M. P. Stryker, J. Physiol. 281, 267 (1978); C. J. Shatz, Neuron 5, 745 (1990).
4. F. Conquet et al., Nature 372, 237 (1994); A. Aiba et al., Cell 79, 365 (1994).
5. F. Conquet et al., Nature 372, 237 (1994); A. Aiba et al., Cell 79, 365 (1994).
6. G Riedel, G Casabona, K. G. Reymann, J. Neurosci. 15, 87 (1995); G. Richter-Levin, M. L. Errington, H. Maegawa, T. V P Bliss, Neuropharmacology 33, 853 (1994); G. Riedel, W. Wetzel, K G. Reymann, Neurosci. Lett 167, 141 (1994).
7. G Riedel, G Casabona, K. G. Reymann, J. Neurosci. 15, 87 (1995); G. Richter-Levin, M. L. Errington, H. Maegawa, T. V P Bliss, Neuropharmacology 33, 853 (1994); G. Riedel, W. Wetzel, K G. Reymann, Neurosci. Lett 167, 141 (1994).
8. G Riedel, G Casabona, K. G. Reymann, J. Neurosci. 15, 87 (1995); G. Richter-Levin, M. L. Errington, H. Maegawa, T. V P Bliss, Neuropharmacology 33, 853 (1994); G. Riedel, W. Wetzel, K G. Reymann, Neurosci. Lett 167, 141 (1994).
9. Z. I. Bashir et al., Nature 363, 347 (1993).
10. S. M. Dudek and M. F. Bear, J. Neurosci. 13, 2910 (1993), S. M. Dudek, F. W Hester, M J Friedlander, Soc Neurosci Abstr 20, 605 8 (1994).
11. S. M. Dudek and M. F. Bear, J. Neurosci. 13, 2910 (1993), S. M. Dudek, F. W Hester, M J Friedlander, Soc Neurosci Abstr 20, 605 8 (1994).
12. V Y. Bolshakov and S. A Siegelbaum, Science 264, 1148 (1994); Z. I. Bashir et al., Eur. J. Pharmacol. 239, 265 (1993); X-D Yang, J. A. Connor, D S. Faber, J. Neurophysiol. 71, 1586 (1994); P.-L. YI et al , Neurosci. Lett 185, 207 (1995); Z. I. Bashir and G. L. Collingridge, Exp. Brain Res. 100, 437 (1994); S M O'Mara, M. J. Rowan, R. Anwyl, Neuropharmacology 34, 983 (1995) [but see D K. Selig et al., J. Neurophysiol. 74, 1075 (1995)]
13. V Y. Bolshakov and S. A Siegelbaum, Science 264, 1148 (1994); Z. I. Bashir et al., Eur. J. Pharmacol. 239, 265 (1993); X-D Yang, J. A. Connor, D S. Faber, J. Neurophysiol. 71, 1586 (1994); P.-L. YI et al , Neurosci. Lett 185, 207 (1995); Z. I. Bashir and G. L. Collingridge, Exp. Brain Res. 100, 437 (1994); S M O'Mara, M. J. Rowan, R. Anwyl, Neuropharmacology 34, 983 (1995) [but see D K. Selig et al., J. Neurophysiol. 74, 1075 (1995)]
14. V Y. Bolshakov and S. A Siegelbaum, Science 264, 1148 (1994); Z. I. Bashir et al., Eur. J. Pharmacol. 239, 265 (1993); X-D Yang, J. A. Connor, D S. Faber, J. Neurophysiol. 71, 1586 (1994); P.-L. YI et al , Neurosci. Lett 185, 207 (1995); Z. I. Bashir and G. L. Collingridge, Exp. Brain Res. 100, 437 (1994); S M O'Mara, M. J. Rowan, R. Anwyl, Neuropharmacology 34, 983 (1995) [but see D K. Selig et al., J. Neurophysiol. 74, 1075 (1995)]
15. V Y. Bolshakov and S. A Siegelbaum, Science 264, 1148 (1994); Z. I. Bashir et al., Eur. J. Pharmacol. 239, 265 (1993); X-D Yang, J. A. Connor, D S. Faber, J. Neurophysiol. 71, 1586 (1994); P.-L. YI et al , Neurosci. Lett 185, 207 (1995); Z. I. Bashir and G. L. Collingridge, Exp. Brain Res. 100, 437 (1994); S M O'Mara, M. J. Rowan, R. Anwyl, Neuropharmacology 34, 983 (1995) [but see D K. Selig et al., J. Neurophysiol. 74, 1075 (1995)]
16. V Y. Bolshakov and S. A Siegelbaum, Science 264, 1148 (1994); Z. I. Bashir et al., Eur. J. Pharmacol. 239, 265 (1993); X-D Yang, J. A. Connor, D S. Faber, J. Neurophysiol. 71, 1586 (1994); P.-L. YI et al , Neurosci. Lett 185, 207 (1995); Z. I. Bashir and G. L. Collingridge, Exp. Brain Res. 100, 437 (1994); S M O'Mara, M. J. Rowan, R. Anwyl, Neuropharmacology 34, 983 (1995) [but see D K. Selig et al., J. Neurophysiol. 74, 1075 (1995)]
17. V Y. Bolshakov and S. A Siegelbaum, Science 264, 1148 (1994); Z. I. Bashir et al., Eur. J. Pharmacol. 239, 265 (1993); X-D Yang, J. A. Connor, D S. Faber, J. Neurophysiol. 71, 1586 (1994); P.-L. YI et al , Neurosci. Lett 185, 207 (1995); Z. I. Bashir and G. L. Collingridge, Exp. Brain Res. 100, 437 (1994); S M O'Mara, M. J. Rowan, R. Anwyl, Neuropharmacology 34, 983 (1995) [but see D K. Selig et al., J. Neurophysiol. 74, 1075 (1995)]
18. V Y. Bolshakov and S. A Siegelbaum, Science 264, 1148 (1994); Z. I. Bashir et al., Eur. J. Pharmacol. 239, 265 (1993); X-D Yang, J. A. Connor, D S. Faber, J. Neurophysiol. 71, 1586 (1994); P.-L. YI et al , Neurosci. Lett 185, 207 (1995); Z. I. Bashir and G. L. Collingridge, Exp. Brain Res. 100, 437 (1994); S M O'Mara, M. J. Rowan, R. Anwyl, Neuropharmacology 34, 983 (1995) [but see D K. Selig et al., J. Neurophysiol. 74, 1075 (1995)]
19. N. Kato, Proc. Natl Acad Sci. U.S A 90, 3650 (1993); H Haruta et al., Neuroreport 5, 1829 (1994).
20. N. Kato, Proc. Natl Acad Sci. U.S A 90, 3650 (1993); H Haruta et al., Neuroreport 5, 1829 (1994).
21. N. A. Hartell, Neuroreport 5, 913 (1994); R Shigemoto et al., Neuron 12, 1245 (1994); A. Aiba et al , Cell 79, 377 (1994), age dependence of cerebellar LTD has not yet been established.
22. N. A. Hartell, Neuroreport 5, 913 (1994); R Shigemoto et al., Neuron 12, 1245 (1994); A. Aiba et al , Cell 79, 377 (1994), age dependence of cerebellar LTD has not yet been established.
23. N. A. Hartell, Neuroreport 5, 913 (1994); R Shigemoto et al., Neuron 12, 1245 (1994); A. Aiba et al , Cell 79, 377 (1994), age dependence of cerebellar LTD has not yet been established.
24. S. N. M Reid, C. Romano, T. Hughes, N W. Daw, J. Comp. Neurol 355, 470 (1995), S. N. M. Reid, C Romano, T. Hughes, D. Devlin, N W. Daw, Soc Neurosci. Abstr. 21, 795 7 (1995); M. V. Catania et al., Neuroscience 61, 481 (1994).
25. S. N. M Reid, C. Romano, T. Hughes, N W. Daw, J. Comp. Neurol 355, 470 (1995), S. N. M. Reid, C Romano, T. Hughes, D. Devlin, N W. Daw, Soc Neurosci. Abstr. 21, 795 7 (1995); M. V. Catania et al., Neuroscience 61, 481 (1994).
26. S. N. M Reid, C. Romano, T. Hughes, N W. Daw, J. Comp. Neurol 355, 470 (1995), S. N. M. Reid, C Romano, T. Hughes, D. Devlin, N W. Daw, Soc Neurosci. Abstr. 21, 795 7 (1995); M. V. Catania et al., Neuroscience 61, 481 (1994).
27. S M Dudek and M F. Bear, Science 246, 673 (1989); W W.-G. Jia, Y. Lin, M Cynader, Dev. Brain Res. 85, 109 (1995).
28. S M Dudek and M F. Bear, Science 246, 673 (1989); W W.-G. Jia, Y. Lin, M Cynader, Dev. Brain Res. 85, 109 (1995).
29. S. LeVay, M P. Stryker, C. J. Shatz, J. Comp Neurol. 179, 223 (1978), A. Antonini and M P. Stryker, J. Neurosci. 13, 3549 (1993).
30. S. LeVay, M P. Stryker, C. J. Shatz, J. Comp Neurol. 179, 223 (1978), A. Antonini and M P. Stryker, J. Neurosci. 13, 3549 (1993).
31. A. Kirkwood, S. M. Dudek, J. T. Gold, C. D. Aizenman, M F Bear, Science 260, 1518 (1993); A. Kirkwood and M. F. Bear, J. Neurosci. 14, 3404 (1994); A. Kirkwood, H.-K. Lee, M. F. Bear, Nature 375, 328 (1995).
32. A. Kirkwood, S. M. Dudek, J. T. Gold, C. D. Aizenman, M F Bear, Science 260, 1518 (1993); A. Kirkwood and M. F. Bear, J. Neurosci. 14, 3404 (1994); A. Kirkwood, H.-K. Lee, M. F. Bear, Nature 375, 328 (1995).
33. A. Kirkwood, S. M. Dudek, J. T. Gold, C. D. Aizenman, M F Bear, Science 260, 1518 (1993); A. Kirkwood and M. F. Bear, J. Neurosci. 14, 3404 (1994); A. Kirkwood, H.-K. Lee, M. F. Bear, Nature 375, 328 (1995).
34. U Drager, J. Neurophysiol. 41, 28 (1978); M Fagiolini et al., Vision Res. 34, 709 (1994). J. A. Gordon and M. P Stryker [J. Neurosci, in press] show that ocular dominance plasticity in mouse primary visual cortex is subject to the same conditions and occurs in the same way as in the cat, involving both intracortical and thalamocortical changes (1).
35. U Drager, J. Neurophysiol. 41, 28 (1978); M Fagiolini et al., Vision Res. 34, 709 (1994). J. A. Gordon and M. P Stryker [J. Neurosci, in press] show that ocular dominance plasticity in mouse primary visual cortex is subject to the same conditions and occurs in the same way as in the cat, involving both intracortical and thalamocortical changes (1).
36. U Drager, J. Neurophysiol. 41, 28 (1978); M Fagiolini et al., Vision Res. 34, 709 (1994). J. A. Gordon and M. P Stryker [J. Neurosci, in press] show that ocular dominance plasticity in mouse primary visual cortex is subject to the same conditions and occurs in the same way as in the cat, involving both intracortical and thalamocortical changes (1).
37. 2, and 11 glucose. Extracellular pipettes (1 M NaCl, 1-3 megohm) monitored stable, half-maximal baseline field potentials evoked from layer IV by a bipolar Pt-lr electrode delivering 100-μs pulses at 0.1 Hz. Five episodes of TBS were given at 10-s intervals to induce LTP before depotentiation was attempted with 900 pulses at 1 Hz A single TBS consisted of 10 repetitions of four stimuli at 100 Hz delivered at 200-ms intervals (12). All experiments were terminated by bath application of 10 μM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, Tocns, UK) and 50 μM D-(-)-2-amino-5-phosphonovaleric acid (D-APV, Sigma) to determine the synaptic component of the field response. Similar results were obtained by measurements of synaptic slope or peak amplitude normalized to the baseline period before TBS, and renormalized to the 10 min preceding 1-Hz stimulation to adjust for variable elapsed time post-TBS across experiments. Both LTP and depotentiation were prevented by the N-methyl-D-aspartate receptor antagonist APV, as also reported for LTD of naïve synapses (12). R,S-α-MCPG or (+)-MCPG (Tocris) were dissolved in 100 mM NaOH at 50 mM, then diluted to 500 μM in ACSF.
38. K R. Stratton, P. F. Worley, J. M. Baraban, Eur. J. Pharmacol. 186, 357 (1990); S. Charpak, B. H. Gähwiler, K. Q. Do, T. Knopfel, Nature 347, 765 (1990); R W. Gereau and P. J. Conn, J. Neurophysiol. 74, 122 (1995); A Baskys. Trends Neurosci. 15, 92 (1992).
39. K R. Stratton, P. F. Worley, J. M. Baraban, Eur. J. Pharmacol. 186, 357 (1990); S. Charpak, B. H. Gähwiler, K. Q. Do, T. Knopfel, Nature 347, 765 (1990); R W. Gereau and P. J. Conn, J. Neurophysiol. 74, 122 (1995); A Baskys. Trends Neurosci. 15, 92 (1992).
40. K R. Stratton, P. F. Worley, J. M. Baraban, Eur. J. Pharmacol. 186, 357 (1990); S. Charpak, B. H. Gähwiler, K. Q. Do, T. Knopfel, Nature 347, 765 (1990); R W. Gereau and P. J. Conn, J. Neurophysiol. 74, 122 (1995); A Baskys. Trends Neurosci. 15, 92 (1992).
41. K R. Stratton, P. F. Worley, J. M. Baraban, Eur. J. Pharmacol. 186, 357 (1990); S. Charpak, B. H. Gähwiler, K. Q. Do, T. Knopfel, Nature 347, 765 (1990); R W. Gereau and P. J. Conn, J. Neurophysiol. 74, 122 (1995); A Baskys. Trends Neurosci. 15, 92 (1992).
42. 3-guanosine 5′-triphosphate (3 to 8 megohm, pH 7 2, 290 to 300 mOsm), t-ACPD (Tocris) was dissolved in ACSF and bath applied.
43. x is the number within ocular dominance group x.
44. In each hemisphere, multibarreled iontophoretic pipettes were lowered into striate cortex just beyond the most distant penetration site used for determination of ocular dominance (<2 mm from cannula). Activation thresholds for kainic acid and t-ACPD (both 20 mM in saline) were determined by gradually increasing iontophoretic ejection currents (WPI model 160) in 20-nA steps once every 60 s. Each round of iontophoresis was preceded by isolation of multiple units with visual stimulation and concluded by verifying the presence of the same visually driven cells. Additional iontophoretic penetrations amidst the single-unit sites and well beyond (>3 mm) confirmed that all shifted cells lay within a region in which mGluRs were blocked.
45. K. Lingenhöhl, H.-R. Olpe, N. Bendali, T. Knöpfel, Neurosci. Res. 18, 229 (1993); P. M. B. Cahusac, Eur. J. Neurosci. 6, 1505 (1994); D E. Jane et al., Neuropharmacology 32, 725 (1993).
46. K. Lingenhöhl, H.-R. Olpe, N. Bendali, T. Knöpfel, Neurosci. Res. 18, 229 (1993); P. M. B. Cahusac, Eur. J. Neurosci. 6, 1505 (1994); D E. Jane et al., Neuropharmacology 32, 725 (1993).
47. K. Lingenhöhl, H.-R. Olpe, N. Bendali, T. Knöpfel, Neurosci. Res. 18, 229 (1993); P. M. B. Cahusac, Eur. J. Neurosci. 6, 1505 (1994); D E. Jane et al., Neuropharmacology 32, 725 (1993).
48. A. Antonini and M P Stryker, Science 260, 1819 (1993).
49. _, J Comp. Neurol., in press
50. C R. Olson and R. D. Freeman, J. Neurophysiol. 38, 26 (1975); C. Blakemore, M J. Hawken, R F. Mark, J. Physiol. (London) 327, 489 (1982), L Mioche and W. Singer, J. Neurophysiol. 62, 185 (1989); T K. Hensch et al , Soc. Neurosci Abstr. 21, 795.4 (1995).
51. C R. Olson and R. D. Freeman, J. Neurophysiol. 38, 26 (1975); C. Blakemore, M J. Hawken, R F. Mark, J. Physiol. (London) 327, 489 (1982), L Mioche and W. Singer, J. Neurophysiol. 62, 185 (1989); T K. Hensch et al , Soc. Neurosci Abstr. 21, 795.4 (1995).
52. C R. Olson and R. D. Freeman, J. Neurophysiol. 38, 26 (1975); C. Blakemore, M J. Hawken, R F. Mark, J. Physiol. (London) 327, 489 (1982), L Mioche and W. Singer, J. Neurophysiol. 62, 185 (1989); T K. Hensch et al , Soc. Neurosci Abstr. 21, 795.4 (1995).
53. C R. Olson and R. D. Freeman, J. Neurophysiol. 38, 26 (1975); C. Blakemore, M J. Hawken, R F. Mark, J. Physiol. (London) 327, 489 (1982), L Mioche and W. Singer, J. Neurophysiol. 62, 185 (1989); T K. Hensch et al , Soc. Neurosci Abstr. 21, 795.4 (1995).
54. S. Nakanishi and M Masu, Annu. Rev. Biophys. Biomol. Struct. 23, 319 (1994), J.-P. Pin and R Duvoisin, Neuropharmacology 34, 1 (1995)
55. S. Nakanishi and M Masu, Annu. Rev. Biophys. Biomol. Struct. 23, 319 (1994), J.-P. Pin and R Duvoisin, Neuropharmacology 34, 1 (1995)
56. Y. Hayashi et al., J. Neurosci. 14, 3370 (1994); C. Thomsen, E. Boel, P. D. Suzdak, Eur. J. Pharmacol. 267, 77 (1994).
57. Y. Hayashi et al., J. Neurosci. 14, 3370 (1994); C. Thomsen, E. Boel, P. D. Suzdak, Eur. J. Pharmacol. 267, 77 (1994).
58. E F Birse et al., Neuroscience 52, 481 (1993); S. A. Eaton et al., Eur. J. Pharmacol. 244, 195 (1993)
59. E F Birse et al., Neuroscience 52, 481 (1993); S. A. Eaton et al., Eur. J. Pharmacol. 244, 195 (1993)
60. J. A. Saugstad, T. P. Segerson, G. L Westbrook, Eur. J. Pharmacol. 289, 395 (1995).
61. Although C. Joly et al. [J. Neurosci. 15, 3970 (1995)] suggest, contrary to (26), that racemic R,S-MCPG is not an effective antagonist at mGluR5 splice variants compared with mGluR1, the same laboratory has shown the stereoselective isomer (+)-MCPG to block all known group I mGluRs [I. Brabet et al., Neuropharmacology 34, 895 (1995)], consistent with (26).
62. Although C. Joly et al. [J. Neurosci. 15, 3970 (1995)] suggest, contrary to (26), that racemic R,S-MCPG is not an effective antagonist at mGluR5 splice variants compared with mGluR1, the same laboratory has shown the stereoselective isomer (+)-MCPG to block all known group I mGluRs [I. Brabet et al., Neuropharmacology 34, 895 (1995)], consistent with (26).
63. D. E. Jane et al., Br. J. Pharmacol. 112, 809 (1994); O. J. Manzoni, P E. Castillo, R. A. Nicoll, Neuropharmacology 34, 965 (1995). Only presynaptic mGluR4 is not blocked by MCPG in vitro (24).
64. D. E. Jane et al., Br. J. Pharmacol. 112, 809 (1994); O. J. Manzoni, P E. Castillo, R. A. Nicoll, Neuropharmacology 34, 965 (1995). Only presynaptic mGluR4 is not blocked by MCPG in vitro (24).
65. O. Manzoni, M. G. Weisskopf, R A Nicoll, Eur. J. Neurosci. 6, 1050 (1994); P Chinestra, L Anikstejn, D. Diabira, Y Ben-An, J. Neurophysiol. 70, 2684 (1993); A. Y. Hsia et al., Neuropharmacology 34, 1567 (1995).
66. O. Manzoni, M. G. Weisskopf, R A Nicoll, Eur. J. Neurosci. 6, 1050 (1994); P Chinestra, L Anikstejn, D. Diabira, Y Ben-An, J. Neurophysiol. 70, 2684 (1993); A. Y. Hsia et al., Neuropharmacology 34, 1567 (1995).
67. O. Manzoni, M. G. Weisskopf, R A Nicoll, Eur. J. Neurosci. 6, 1050 (1994); P Chinestra, L Anikstejn, D. Diabira, Y Ben-An, J. Neurophysiol. 70, 2684 (1993); A. Y. Hsia et al., Neuropharmacology 34, 1567 (1995).
68. Z. A. Bortolotto, Z. I. Bashir, C. H. Davies, G. L. Collingridge, Nature 368, 740 (1994).
69. We thank S. Harns for assistance during the implant surgeries, and M. Fagiolini and R. A. Nicoll for critical comments on the manuscript. T.K.H. is a Howard Hughes Medical Institute Predoctoral Fellow Supported by grants to M.P.S from the National Institutes of Health (EY02874) and the Human Frontiers Science Program (RG69/93).